Hye Duck Choi
Overview
Explore the profile of Hye Duck Choi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shin K, Choi H
Int J Clin Pharmacol Ther
. 2024 Mar;
62(6):250-258.
PMID: 38529927
Objectives: Although the clinical role of protein convertase subtilisin kexin type 9 (PCSK9) inhibitors for cholesterol management is increasing, the post-marketing period of use is short compared to other lipid-lowering...
2.
Shin K, Ah Y, Cha S, Choi H
PLoS One
. 2023 Jun;
18(6):e0287382.
PMID: 37327237
Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study...
3.
Choi H, Kim J
Cardiovasc Ther
. 2023 Jan;
2023:7362551.
PMID: 36704607
Background: Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of...
4.
Ah Y, Jeong M, Choi H
PLoS One
. 2022 Mar;
17(3):e0264437.
PMID: 35245303
Statin is highly recommended for dyslipidemia to prevent atherosclerosis-related cardiovascular diseases and death. The aim of this study was to compare the efficacies and safeties of low/moderate-intensity statin plus ezetimibe...
5.
Shin K, Choi H
Am J Cardiovasc Drugs
. 2021 Dec;
22(4):395-406.
PMID: 34927215
Introduction: Dyslipidemia in diabetes mellitus is characterized by hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and elevated low-density lipoprotein cholesterol (LDL-C). Additionally, the potentially increased risk of morbidity and mortality following...
6.
Yang B, Heo K, Yu Y, Yeom G, Choi H, Lee J, et al.
Int J Environ Res Public Health
. 2021 Jun;
18(10).
PMID: 34065935
Media has become a major source of information on health and plays a role in the decision-making process on health topics. We aimed to evaluate the association between zolpidem use...
7.
Choi H, Chang M
PLoS One
. 2020 Jul;
15(7):e0234818.
PMID: 32663210
Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin rash and diarrhea are well-known and common...
8.
Yang K, Yong C, Choi H, Kim J
Asia Pac J Clin Nutr
. 2019 Aug;
28(3):476-485.
PMID: 31464394
Background And Objectives: Obesity and diet contribute to the development of hypercholesterolemia; therefore, controlling blood lipid concentration through diet is essential. To understand the role of diet in controlling blood...
9.
Choi H, Chae S
Medicine (Baltimore)
. 2018 Dec;
97(50):e13593.
PMID: 30558030
Objective: Dyslipidemia is a major risk factor for the development of cardiovascular disease. Both statins and omega-3 fatty acids demonstrate beneficial effects on lipid concentrations. The goal was to evaluate...
10.
Choi H, Chang M
Breast Cancer Res Treat
. 2017 Aug;
166(3):927-936.
PMID: 28825152
Purpose: Lapatinib is a tyrosine kinase inhibitor that targets the human epidermal growth factor receptor 2 (HER2) and the epidermal growth factor receptor (EGFR/HER1), and there are concerns about its...